Rebecca has over 20 years of experience in design and management of Clinical Trials both in the UK and in Australia.

Rebecca joined CTC in 2005 as Project Manager for the ASPIRE trial, which ended in 2012. ASPIRE looked at the use of aspirin for secondary prevention of Venous Thromboembolism (VTE) and recruited patients from Australia, New Zealand.

Rebecca leads the Cardiometabolic Trials team at CTC responsible for the development of new trials as well as management of existing trials within the portfolio. She is also responsible for Ethics questions, including oversight of the Ethics Co-ordinator team and CTC Oracle.

In 2018, Rebecca was awarded the Sydney Medical School Award for Exceptional Performance by Professional Staff.